Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) EBIT: 2016-2024

Historic EBIT for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to -$241.4 million.

  • Autolus Therapeutics' EBIT fell 5.52% to -$71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$273.9 million, marking a year-over-year decrease of 25.18%. This contributed to the annual value of -$241.4 million for FY2024, which is 34.35% down from last year.
  • Autolus Therapeutics' EBIT amounted to -$241.4 million in FY2024, which was down 34.35% from -$179.7 million recorded in FY2023.
  • Autolus Therapeutics' EBIT's 5-year high stood at -$141.1 million during FY2021, with a 5-year trough of -$241.4 million in FY2024.
  • Moreover, its 3-year median value for EBIT was -$179.7 million (2023), whereas its average is -$188.2 million.
  • Per our database at Business Quant, Autolus Therapeutics' EBIT grew by 16.11% in 2021 and then tumbled by 34.35% in 2024.
  • Yearly analysis of 5 years shows Autolus Therapeutics' EBIT stood at -$168.1 million in 2020, then rose by 16.11% to -$141.1 million in 2021, then decreased by 1.67% to -$143.4 million in 2022, then fell by 25.31% to -$179.7 million in 2023, then crashed by 34.35% to -$241.4 million in 2024.